Table 3.
Abnormal parameter rates from the blood samples in the common COVID‐19, severe COVID‐19, and influenza groups
| Common group (N = 145) | Severe group (N = 24) | Influenza (N = 131) | P a | P b | P c | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference interval | Overall (N = 169) N (%) | Overall N (%) | Below the lower reference limit N (%) | Above the higher reference limit N (%) | Overall N (%) | Below the lower reference limit N (%) | Above the higher reference limit N (%) | Overall N (%) | Below the lower reference limit N (%) | Above the higher reference limit N (%) | ||||
| WBC (×109/L) | 3.5‐9.5 | 33 (19.5) | 30 (20.7) | 29 (20.0) | 1 (0.7) | 3 (12.5) | 3 (12.5) | 0 (0) | 22 (16.8) | 10 (7.6) | 12 (9.2) | .510 | .409 | .768 |
| RBC (×1012/L) | Male: 4.30‐5.80 Female: 3.80‐5.10 | 20 (11.8) | 18 (12.4) | 9 (6.2) | 9 (6.2) | 2 (8.3) | 2 (8.3) | 0 (0) | 28 (21.3) | 18 (13.7) | 10 (7.6) | .816 | .046 | .0169 |
| Hb, g/L | Male: 130‐175 Female: 115‐150 | 23 (13.6) | 19 (13.1) | 18 (12.4) | 1 (0.7) | 4 (16.7) | 4 (16.7) | 0 (0) | 22 (16.8) | 20 (15.3) | 2 (1.5) | .881 | .389 | 1.000 |
| PLT (×109/L) | 125‐350 | 24 (14.2) | 17 (11.7) | 14 (9.7) | 3 (2.1) | 7 (29.2) | 6 (25.0) | 1 (4.2) | 17 (13.0) | 13 (9.9) | 4 (3.1) | .051 | .752 | .062 |
| NE% | 40.0‐75.0 | 35 (20.7) | 22 (15.2) | 2 (1.4) | 20 (13.8) | 13 (54.2) | 1 (4.2) | 12 (50.0) | 51 (38.9) | 8 (6.1) | 43 (32.8) | .000 | .000 | .163 |
| LY% | 20.0‐50.0 | 50 (29.6) | 36 (24.8) | 35 (24.1) | 1 (0.7) | 14 (58.3) | 13 (54.2) | 1 (4.2) | 79 (60.3) | 73 (55.7) | 6 (4.6) | .001 | .000 | .856 |
| MO% | 3.0‐10.0 | 41 (24.3) | 35 (24.1) | 0 (0) | 35 (24.1) | 6 (25.0) | 1 (4.2) | 5 (20.8) | 51 (38.9) | 0 (0) | 51 (38.9) | .927 | .008 | .193 |
| EO% | 0.4‐8.0 | 47 (27.8) | 32 (22.1) | 31 (21.4) | 1 (0.7) | 15 (62.5) | 15 (62.5) | 0 (0) | 60 (45.8) | 60 (45.8) | 0 (0) | .000 | .000 | .132 |
| BA% | 0‐1.0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | … | … | … |
| NE# (×109/L) | 1.8‐6.3 | 26 (15.4) | 21 (14.5) | 18 (12.4) | 3 (2.1) | 5 (20.8) | 3 (12.5) | 2 (8.3) | 38 (29.0) | 13 (9.9) | 25 (19.1) | .622 | .003 | .411 |
| LY# (×109/L) | 1.1‐3.2 | 80 (47.3) | 61 (42.1) | 58 (40.0) | 3 (2.1) | 19 (79.2) | 19 (79.2) | 0 (0) | 71 (54.2) | 69 (52.7) | 2 (1.5) | .001 | .044 | .023 |
| MO# (×109/L) | 0.1‐0.6 | 13 (7.7) | 11 (7.6) | 2 (1.4) | 9 (6.2) | 2 (8.3) | 1 (4.2) | 1 (4.2) | 48 (36.6) | 0 (0) | 48 (36.6) | 1.000 | .000 | .006 |
| EO# (×109/L) | 0.02‐0.52 | 46 (27.2) | 32 (22.1) | 32 (22.1) | 0 (0) | 14 (58.3) | 14 (58.3) | 0 (0) | 53 (40.5) | 53 (40.5) | 0 (0) | .000 | .001 | .104 |
| BA# (×109/L) | 0.00‐0.06 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | … | … | … |
Abbreviations: BA#, basophil count; BA%, percentage of basophil; COVID‐19, coronavirus disease 2019; EO#, eosinophil count; EO%, percentage of eosinophil; Hb, haemoglobin; LY#, lymphocyte count; LY%, percentage of lymphocyte; MO#, monocyte count; MO%, percentage of monocytes; NE#, neutrophil count; NE%, percentage of neutrophils; PLT, platelet; RBC, red blood cell; WBC, white blood cell.
a
Comparison of total abnormal rate between common and severe groups.
b
Comparison of total abnormal rate between common and influenza groups.
c
Comparison of total abnormal rate between severe and influenza groups.